PDGFRA and Chronic Eosinophilic Leukemia, Not Otherwise Specified: According to the report by Helbig et al. (2008), very low dose imatinib therapy (100 mg/week) for CEL with PDGFRA‐FIP1L1 fusion gene successfully maintained remission during the observation period.